Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a tablet for oral use. It is used for medical termination of intrauterine pregnancy up to 10 weeks gestation. GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifegyne acts as a progesterone receptor antagonist in early pregnancy termination. - Medical termination of intrauterine pregnancy up to 10 weeks: induces decidual breakdown and expulsion of the gestational sac. - Adjunct to misoprostol in medical abortion: enhances the efficacy of misoprostol‑induced uterine contractions. - Pre‑treatment before surgical abortion: reduces uterine vascularity and bleeding, facilitating safer surgical procedures.

Mifegyne may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Vomiting - Abdominal cramping - Vaginal bleeding - Diarrhoea - Fatigue

Serious or Rare Side Effects: - Severe infection (sepsis) - Heavy bleeding requiring transfusion - Allergic reaction (anaphylaxis) - Liver injury - Uterine rupture - Persistent ectopic pregnancy

Mifegyne should be used only under medical supervision with appropriate patient selection. - Confirm gestational age: ensure pregnancy is ≤10 weeks by ultrasound. - Verify intrauterine location: exclude ectopic pregnancy before administration. - Use in combination with misoprostol: follow approved regimen for optimal efficacy. - Contraindicated in chronic adrenal insufficiency or long‑term corticosteroid therapy. - Store at below 25°C: keep in the original pack, protect from moisture.

Mifegyne may interact with other medicines that affect its metabolism or hormonal balance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase mifepristone plasma levels. - Antifungal agents that inhibit CYP3A4: may raise drug exposure. - Antiretroviral protease inhibitors (e.g., ritonavir): potentiate pharmacologic effects.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal bleeding. - Hormonal contraceptives: progesterone antagonism can reduce contraceptive efficacy. - Anticoagulants: enhanced bleeding tendency when combined with misoprostol‑induced uterine activity.